Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

Conditions:   HER2-Negative Metastatic Breast Cancer;   Recurrent Ovarian Cancer Interventions:   Drug: Durvalumab;   Drug: Eribulin Sponsors:   Amy Tiersten;   AstraZeneca;   Eisai Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials